Keywords: Contrast Agent, Blood vesselsIron Dextran is a widely used FDA-approved ultra-small-superparamagnetic-iron-oxides (USPIO) to treat iron deficiency anemia in patients. Here, we evaluate the feasibility of using Iron Dextran as an MRI contrast agent for imaging arterial and venous blood vessels using multi-echo susceptibility weighted imaging (SWI) MRI at 7T. Phantom experiments were performed to measure relaxivity values (r1 and r2) for Iron Dextran in blood. Pre- and post-infusion MRI images were acquired in human subjects from which maps of arteries and veins were extracted. The post-contrast SWI images showed enhanced susceptibility difference between blood and the surrounding tissue in both arteries and veins.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords